

Date: 11.11.2021

To,

BSE Limited Phiroze JeeJeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Scrip Code: 543318 National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 Trading Symbol: CLEAN

Dear Sir/Madam,

Subject: Investor Presentation.

In accordance with Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Financial Results presentation for quarter and half year ended 30th September 2021 is enclosed.

The aforesaid presentation is also available on the Company's website.

14301 pue

You are requested to take the same on record.

Thanking You.

For Clean Science and Technology Limited

Mahesh Kulkarni **Company Secretary**

(Erstwhile known as Clean Science and Technology Private Limited) Regd. Office: 503, Pentagon Tower 4, Magarpatta City, Hadapsar, Pune - 411013, MS, India Tel: +91 20 26899953 Fax: +91 20 26898894 Email: corporate@cleanscience.co.in Website: www.cleanscience.co.in CIN: L24114PN2003PLC018532



Clean Science and Technology Limited

innovation at work

Q2 FY 2022 RESULTS PRESENTATION November 2021

UPDATES FOR THE QUARTER 2, FY2022

KEY UPDATES DURING THE QUARTER

Resilient quarterly performance and steadfast commitment towards capex



Resilient


• Despite steep increase in raw material prices, gross margins for Q2 FY2022 remained healthy at ~ 68%

performance

Capex

commitment





P&L OVERVIEW – STEADY REVENUES AND RESILIENT MARGIN



Key short term concerns: steep increase in input prices, logistical challenges

Particulars (INR Crore)	Q2 FY 2022	Q1 FY 2022	Q-o-Q (%)	Q2 FY 2021	Y-o-Y (%)	H1 FY 2022	H1 FY 2021	Y-o-Y (%)
Revenue from product sales	151.7	144.7	5%	138.9	9%	296.3	250.2	18%
Other operating income	1.5	1.6		1.4		3.1	2.9	
Total Revenue	153.2	146.3	5%	140.2	9%	299.5	253.1	18%
Raw material cost	48.0	42.2	14%	34.8	38%	90.2	64.7	39%
Operating expenses	36.4	32.8	11%	35.2	3%	69.2	62.0	11%
EBITDA	68.7	71.3	(4)%	70.2	(2)%	140.1	126.4	11%
EBITDA %	45.3%	49.3%		50.6%		47.3%	50.5%	
Depreciation costs	6.1	5.8	5%	4.0	51%	11.9	8.2	45%
Other Income	8.6	6.5	32%	7.6	14%	15.1	12.8	18%
РВТ	71.2	72.1	(1)%	73.8	(3)%	143.3	131.0	9%
PBT %	47.0%	49.8%		53.1%		48.4%	52.4%	
РАТ	53.5	54.6	(2)%	54.3	(1)%	108.1	96.2	12%
PAT %	35.3%	37.7%		39.1%		36.5%	38.4%	

BALANCE SHEET SUMMARY

Lean working capital cycle of 60 days and nil debt



In INR Crore	As at 30 Sept. 2021	As at 31 March 2021		
Assets				
Fixed Assets	233.4	182.9		
Capital work-in-progress	41.7	55.0		
Right of use asset	14.0	3.0		
Other non-current assets	20.4	25.0		
Total non-current assets	309.5	265.9		
Inventories	69.1	52.9		
Investments	213.2	231.5		
Trade receivables	86.9	74.2		
Cash and bank balances	60.4	15.6		
Other current assets	22.5	20.2		
Total current assets	452.0	394.4		
Total assets	761.5	660.3		
	Equity and Liabilities			
Net-worth	648.3	540.0		
Borrowings	0.3	0.3		
Provisions	0.5	0.4		
Deferred tax liabilities (net)	17.9	17.6		
Total non-current liabilities	18.7	18.3		
Trade payables	69.5	61.0		
Other current liabilities	25.0	41.0		
Total current liabilities	94.5	102.0		
Total equity and liabilities	761.5	660.3		


Key metrics	H1 FY22	FY 2021
Return on Equity	33.4%	36.7%
Return on Capital Employed	60.9%	73.9%
Inventory days	123	129
Receivable days	49	51
Payable days	113	124

Receivable days=(Average Debtors/Sales)*365; Inventory days=(Average Inventory/COGS)*365; Payable days=(Average Payables/Raw material purchase)*365

SALES PROFILE – H1 FY22


Key segments delivering encouraging performance; export markets continue to remain strong





Revenue mix by geography

H1 FY21



■ India ■ China ■ Europe ■ Americas ■ ROW

- Performance chemicals Increased volume offtake across all products and better realization for MEHQ during Q2 FY'22 compared to Q2 FY'21
- Pharma chemical Lower volume and realization during Q2 FY'22 compared to Q2 FY'21, except for DCC where volume improved
- FMCG chemical Lower volume offtake and better realization across all products during Q2 FY'22 compared to Q2 FY'21
- Exports to China continue to be robust


H1 FY22

• Other key geographies are India followed by Europe and Americas

CORPORATE PRESENTATION



- In line with our vision, changed name to Clean Science and Technology
- Started manufacturing 4-MAP
- Started manufacturing Anisole using liquid phase technology
- Started manufacturing DCC




• Started manufacturing MEHQ and Guaiacol

- Started manufacturing BHA
- Started manufacturing Anisole using vapor phase technology in UNIT-2
- Started manufacturing AP
- Started manufacturing Anisole using vapor phase technology in UNIT-3
- Purchased 34 acre land for UNIT-4

KEY DIFFERENTIATORS Helped company develop into a global supplier of critical specialty chemicals in just 15 years





Pioneered commercialization of catalytic-reactions in production processes




R&D Strategy	 Designing catalysts to create new manufacturing processes and new products Develop eco-friendly processes by eliminating use of toxic starting materials Focus on good Atom economy to avoid wastage
R&D Focus	 Improve yields and selectivity in our existing processes Expanding product portfolio across existing segments and adding new segments Identifying products with high demand that only limited manufacturers produce globally
R&D Capabilities	 State of the art technological equipment to develop, test and evaluate products Government of India's Department of Scientific and Industrial Research recognized R&D units 2 R&D units with 35 personnel (including 6 PhD's)

TECHNOCRAT PROMOTERS

Promoters' sole business interest remains Clean Science and Technology with 78.51% stake






ROBUST CORPORATE GOVERNANCE

Distinguished Board of Directors and reputed financial market reviewers





DIVERSIFIED PRODUCT PROFILE

With applications across various critical end-user industries




PRODUCT	APPLICATION	REVENUE (INR Crore)			
	PERFORMANCE CHEMICALS				
 MEHQ (Monomethyl ether of hydroquinone) 	 Polymerization inhibitor in acrylic acids, acrylic esters, super absorbent polymers (diapers and sanitary pads) Pre-cursor for agrochemical industry 	FY 2021	272		
 BHA (Butylated Hydroxy Anisole) 	Anti-oxidant in food and animal feed industry	FY 2019 FY 2018	249		
AP (L-Ascorbyl Palmitate)	 Infant food formulations, breakfast cereals and cosmetics 				
	PHARMACEUTICAL CHEMICALS	FY 2021	83		
> Guaiacol	Pre-cursor to manufacture APIs for cough syrup	FY 2020	64		
 DCC (Dicyclohexyl Carbodiimide) 	Reagent in anti-retroviral	 FY 2019 FY 2018 	50		
	FMCG CHEMICALS	FY 2021	63		
 4-MAP (4-Methoxy Acetophenone) 	Used in UV blocker in sunscreens (cosmetics industry)	FY 2020	67		
> Anisole	Precursor to perfumes, insect pheromones, pharmaceuticals	FY 2019 FY 2018	33		

FY 2021 REVENUE CONTRIBUTION

Diversified customer base and wide product applications across industries






- Strong customer relationships and presence in export markets across multiple countries
- Strong contribution from high value critical performance chemicals segment.

STRONG FINANCIALS

Among the fastest growing and profitable specialty chemical companies globally





Note: RoCE = EBIT (ex. Other income) divided by capital employed (Gross FA + Working Capital); RoNW = PAT as % of net worth

Net Fixed Asset Turnover = Revenue from Operations/Net Fixed Assets; Net Fixed Assets include Property, plant and equipment, Right-of-use asset & Intangible Assets (Nos. in INR crore)

COMMITMENT TOWARDS ESG





ENVIRONMENT (E)

- ✓ Among the few companies globally focused on developing "green", ecofriendly & cost competitive technologies using in-house catalytic processes
- ✓ Eco-friendly production processes ensures zero liquid discharge sites or only water as effluent
- ✓ Not received any material observations from pollution control board in India
- Power consumption from captive solar plants and investments in renewable energy projects



SOCIAL (S)

- ✓ Total contribution towards CSR activities during last 3 years is INR 8.1 crore
- ✓ Focus Areas -
- Education
- Healthcare
- Medical Relief
- Vocational Skills
- Environment Sustainability



CORPORATE GOVERNANCE (G)

- ✓ More than 1/3rd Board members are independent
- ✓ Statutory auditors BSR & Co.
- ✓ Long term & short term ratings by CRISIL are A+ (Stable) and A1+ respectively

DISCLAIMER



Certain statements and opinions with respect to the anticipated future performance of the company in the presentation ("forward - looking statements"), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward - looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward - looking statements only speak as at the date the presentation is provided to the recipient and the company is not under any obligation to update or revise such forward -looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this presentation or that this presentation is suitable for the recipient's purposes. The delivery of this presentation does not imply that the information herein is correct as at any time subsequent to the date hereof and the company has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof